Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
HCM 
HUTCHMED DRC (HCM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
10/21/2025: HCM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
14 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $22.54
1 Year Target Price $22.54
| 9 | Strong Buy |
| 2 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -36.07% | Avg. Invested days 41 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 10/21/2025 |
Key Highlights
Company Size Mid-Cap Stock | Market Capitalization 2.60B USD | Price to earnings Ratio 5.7 | 1Y Target Price 22.54 |
Price to earnings Ratio 5.7 | 1Y Target Price 22.54 | ||
Volume (30-day avg) 14 | Beta 0.48 | 52 Weeks Range 11.51 - 21.50 | Updated Date 10/21/2025 |
52 Weeks Range 11.51 - 21.50 | Updated Date 10/21/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 2.65 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 77.53% | Operating Margin (TTM) -1.27% |
Management Effectiveness
Return on Assets (TTM) -0.81% | Return on Equity (TTM) 46.9% |
Valuation
Trailing PE 5.7 | Forward PE 56.82 | Enterprise Value 1462517530 | Price to Sales(TTM) 4.31 |
Enterprise Value 1462517530 | Price to Sales(TTM) 4.31 | ||
Enterprise Value to Revenue 2.43 | Enterprise Value to EBITDA 38.51 | Shares Outstanding 171867743 | Shares Floating 509024247 |
Shares Outstanding 171867743 | Shares Floating 509024247 | ||
Percent Insiders 0.12 | Percent Institutions 3.64 |
Upturn AI SWOT
HUTCHMED DRC
Company Overview
History and Background
HUTCHMED (China) Limited, formerly Hutchison China MediTech Limited, was founded in 2000. It focuses on discovering, developing, and commercializing innovative therapeutics for oncology and immunology.
Core Business Areas
- Oncology: Research, development, and commercialization of cancer therapies.
- Immunology: Research, development, and commercialization of therapies related to immune system modulation.
- Commercial Platform: Sales and marketing of prescription drugs in China.
Leadership and Structure
Weiguo Su, PhD, is the CEO. The company has a board of directors and operates with functional teams dedicated to R&D, commercialization, and corporate functions.
Top Products and Market Share
Key Offerings
- Elunate (fruquintinib): A highly selective and potent oral inhibitor of VEGFR 1/2/3. Approved in China for metastatic colorectal cancer. Market share is growing in its indicated market. Competitors include regorafenib and trifluridine/tipiracil.
- Sulanda (surufatinib): An oral inhibitor of VEGFR and FGFR. Approved in China for advanced neuroendocrine tumors. Competitors include sunitinib and everolimus.
- Orpathys (savolitinib): A selective MET tyrosine kinase inhibitor. Approved in China for non-small cell lung cancer with MET exon 14 skipping mutations. Competitors include tepotinib and capmatinib.
Market Dynamics
Industry Overview
The pharmaceutical industry is characterized by high R&D costs, lengthy regulatory approval processes, and intense competition. The oncology market, in particular, is rapidly expanding.
Positioning
HUTCHMED DRC is positioning itself as a leading innovative biopharmaceutical company focused on China and global markets, with a strong emphasis on oncology and immunology.
Total Addressable Market (TAM)
The TAM for oncology drugs is substantial, projected to reach hundreds of billions of dollars globally. HUTCHMED DRC is targeting specific niches within this large market, positioning itself for growth.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Innovative drug pipeline
- Commercial presence in China
- Experienced management team
Weaknesses
- Reliance on a few key products
- High R&D expenses
- Geographic concentration (China)
- Profitability concerns
Opportunities
- Expansion into new markets
- Partnerships with other pharmaceutical companies
- New drug approvals
- Expansion of the product pipeline
Threats
- Competition from established pharmaceutical companies
- Regulatory changes
- Pricing pressures
- Clinical trial failures
Competitors and Market Share
Key Competitors
- Eli Lilly and Company (LLY)
- Novartis AG (NVS)
- Sanofi (SNY)
Competitive Landscape
HUTCHMED DRC competes with established pharmaceutical companies. Its advantages include a strong presence in China and innovative drug pipeline, but disadvantages include a smaller scale and limited financial resources.
Growth Trajectory and Initiatives
Historical Growth: Growth has been driven by the successful commercialization of Elunate and Sulanda and Orpathys.
Future Projections: Analysts expect continued revenue growth driven by existing products and new product launches. Profitability is expected to improve over time.
Recent Initiatives: Recent initiatives include expansion into new markets, clinical trials for new indications, and partnerships with other pharmaceutical companies.
Summary
HUTCHMED DRC is an innovative biopharmaceutical company with a promising drug pipeline and strong presence in China. Its focus on oncology and immunology provides significant growth potential. However, the company faces intense competition and high R&D expenses. Continued success hinges on successful drug development, regulatory approvals, and market expansion.
Peer Comparison
Sources and Disclaimers
Data Sources:
- HUTCHMED (China) Limited's Annual Reports
- Company Press Releases
- Industry Analyst Reports
- Financial News Sources
Disclaimers:
This analysis is for informational purposes only and should not be considered financial advice. Market conditions and company performance can change rapidly. Please consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About HUTCHMED DRC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2016-03-17 | Acting CEO, CFO & Executive Director Mr. Chig Fung Cheng BEc, CA | ||
Sector Healthcare | Industry Drug Manufacturers - Specialty & Generic | Full time employees 1780 | Website https://www.hutch-med.com |
Full time employees 1780 | Website https://www.hutch-med.com | ||
HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies to treat cancer and immunological diseases in Hong Kong, the United States, and internationally. The company offers Fruquintinib, a selective and potent oral inhibitor of vascular endothelial growth factor receptors for treatment of colorectal cancer (CRC), breast cancer, gastric cancer (GC), microsatellite stable-CRC endometrial cancer (EMC), non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), endometrial cancer (EMC); and Savolitinib, a potent and selective inhibitor of mesenchymal-epithelial transition receptor to treat NSCLC, papillary RCC, and GC. It also develops Surufatinib to trea pancreatic neuroendocrine tumor (NET), non pancreatic NET, and pancreatic ductal adenocarcinoma; Sovleplenib, to treat immune thrombocytopenic purpura and warm autoimmune hemolytic anemia; and Tazemetostat, a treatment for epithelioid sarcoma and follicular lymphoma; Fanregratinib that treats intrahepatic cholangiocarcinoma; and Ranosidenib, a novel dual-inhibitor of dehydrogenase-1 and isocitrate dehydrogenase-2 enzymes to treat acute myeloid leukemia (AML). In addition, the company is developing HMPL-760, which is in phase I and II clinical trial to treat relapsed and/or refractory diffuse large B cell lymphoma, chronic lymphocytic leukemia, small lymphocytic lymphoma, and other B-NHL; HMPL-506 to treat Mixed-lineage leukemia-rearrange/rearrangement and nucleophosmin 1-mutantAML. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., and Epizyme, Inc., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.